Disease Landscape and Forecast Insights

The major depressive disorder (MDD) therapy market is crowded and highly genericized. The prominent use of generic drugs such as selective serotonin reuptake inhibitors (SSRIs) as early-line…

The treatment of neuropathic pain involves the use of drugs from several classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid…

Clarivate Epidemiology’s coverage of autism spectrum disorder (ASD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Renal anemia is a common complication of chronic kidney disease (CKD). The primary goal of treatment of renal anemia is to increase and maintain Hb levels and reduce the risk of complications of…

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Pirfenidone was the first disease-modifying therapy (DMT) approved for IPF,…

The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics and targeted oral therapies. The well-established TNF-α…

Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in that country by 2033. Treatment of metastatic disease is dominated by…

The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants in established classes such as TG Therapeutics’ Briumvi, Novartis’s Kesimpta,…

Clarivate Epidemiology’s coverage of PAD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total prevalence of PAD for each country, as…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key PAD patient populations, covering 171 countries and more than 99% of…

The renal cell carcinoma (RCC) treatment landscape in China has evolved rapidly since the introduction of targeted therapies, including TKIs (Pfizer’s Sutent and Inlyta, Novartis’s Votrient,…

Clarivate Epidemiology’s coverage of peripheral arterial disease (PAD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PAD…